1920 MCKINNEY AVENUE, DALLAS, TX
Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Investor Presentation
Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Effectiveness Notice
S-1
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload
S-1MEF
Free Writing Prospectus